Finding Heart Failure in Those Prescribed Loop Diuretics in Primary Care in Jersey

NCT07320677 | Enrolling By Invitation

• 1 other identifier: 2025HCJREC03
• Study Type: interventional
• Target: 400
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to learn whether a simple blood test screening pathway can help diagnose heart failure earlier in adults in primary care who take loop diuretic medicines (such as furosemide or bumetanide) but do not have a recorded diagnosis of heart failure. The main questions it aims to answer are:

1. 1.Does offering a NT-proBNP blood test to eligible patients increase the number of new heart failure diagnoses within 12 months compared with usual care?
2. 2.Does this screening pathway also uncover other important heart problems, such as irregular heart rhythms (arrhythmias) or valve disease?
3. 3.NT-proBNP screening pathway, in which eligible patients are invited for a NT-proBNP blood test
4. 4.Usual care, in which patients continue to be managed as they normally would without proactive screening

Conditions

Heart Failure; Diuretics

Keywords

NT-proBNP; Natriuretic peptide; Heart Failure; Screening

Outcome Measures

Primary Outcomes (1)

• New Heart Failure diagnosis at 12 months

  12 months from practice enrollment

Secondary Outcomes (3)

• New clinically relevant cardiovascular disease

  12 months

• Heart Failure Hospitalisations

  12 months

• All cause mortality

  12 months

Other Outcomes (1)

• Number of patients with heart failure but not coded in primary care record

  12 months

Study Arms (2)

Intervention - NTproBNP Screening

EXPERIMENTAL

Half of the island's GP surgeries will be randomly allocated to the intervention arm, whereby patients receiving a loop diuretic but without a diagnosis of heart failure or natriuretic peptide testing will be invited for a point of care NT-proBNP test.

Diagnostic Test: NT-proBNP screening

Control - Usual care

NO INTERVENTION

Half of the island's GP surgeries will be randomly allocated to the control arm, whereby patients will continue with usual clinical care and won't be approached by the study team.

Interventions

NT-proBNP screening DIAGNOSTIC_TEST

Patients in the intervention arm will be invited for a free point of care NT-proBNP blood test

Intervention - NTproBNP Screening

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Receiving a loop diuretic (furosemide, bumetanide or torsemide)
• No coded diagnosis of heart failure in GP records
• Never had a natriuretic peptide test
• Willing to have a blood test for NT-proBNP

You may not qualify if:

• Clinical Frailty Score 7 or above on Rockwood frailty scale
• Prior diagnosis of heart failure
• Prior natriuretic peptide testing

Sponsors & Collaborators

• Government of Jersey: lead

Study Sites (1)

Jersey General Hospital

Saint Helier, Jersey

Location

MeSH Terms

Conditions

Heart Failure

Condition Hierarchy (Ancestors)

Heart Diseases; Cardiovascular Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: PARALLEL
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Cardiology Research Fellow

Study Record Dates

• First Submitted: December 22, 2025
• First Posted: January 6, 2026
• Study Start: November 1, 2025
• Primary Completion (Estimated): March 1, 2027
• Study Completion (Estimated): July 1, 2027
• Last Updated: January 6, 2026

Record last verified: 2025-12

Locations

JE (1)